Literature DB >> 19861994

Refractory neuroendocrine tumor-response to liposomal doxorubicin and capecitabine.

Gianluca Masi1, Lorenzo Fornaro, Samanta Cupini, Fotios Loupakis, Enrico Vasile, Giacomo G Baldi, Irene Stasi, Lisa Salvatore, Alfredo Falcone.   

Abstract

BACKGROUND: A 61-year-old patient with no relevant medical or family history presented with a 2 month history of refractory dry cough that led to the diagnosis of typical carcinoid tumor of the lung metastatic to the mediastinal lymph nodes and liver. She initially received a long-acting somatostatin analog (octreotide) and chemotherapy with cisplatin and etoposide, which was ineffective. INVESTIGATIONS: Physical examination, laboratory test, chromogranin A test, CT scan, (111)In-diethylenetriaminepentaacetic acid (DTPA)-octreotide scan, (18)F-FDG-PET scan, fine-needle and tissue core liver biopsies. DIAGNOSIS: Pulmonary spindle-cell carcinoid tumor with metastases to mediastinal lymph nodes and liver. MANAGEMENT: Systemic treatment with oral capecitabine (1,500 mg/m(2) daily from day 1 to day 21) and intravenous liposomal doxorubicin (10 mg/m(2) on days 1, 8 and 15), both repeated every 4 weeks, administered concomitantly with long-acting octreotide 30 mg every 3 weeks. The patient achieved a significant and long-lasting response with the combination of capecitabine and liposomal doxorubicin. She reported no severe adverse effects.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19861994     DOI: 10.1038/nrclinonc.2009.148

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


  12 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  Octreoscan in patients with bronchial carcinoid tumours.

Authors:  Dan Granberg; Anders Sundin; Eva Tiensuu Janson; Kjell Oberg; Britt Skogseid; Jan-Erik Westlin
Journal:  Clin Endocrinol (Oxf)       Date:  2003-12       Impact factor: 3.478

Review 3.  Cardiovascular complications of malignant carcinoid disease.

Authors:  A S Anderson; D Krauss; R Lang
Journal:  Am Heart J       Date:  1997-10       Impact factor: 4.749

Review 4.  Carcinoid tumors: molecular genetics, tumor biology, and update of diagnosis and treatment.

Authors:  Kjell Oberg
Journal:  Curr Opin Oncol       Date:  2002-01       Impact factor: 3.645

5.  Neuroendocrine neoplasms of the lung: a prognostic spectrum.

Authors:  Hisao Asamura; Toru Kameya; Yoshihiro Matsuno; Masayuki Noguchi; Hirohito Tada; Yuichi Ishikawa; Tomoyuki Yokose; Shi-Xu Jiang; Takeshi Inoue; Ken Nakagawa; Kinuko Tajima; Kanji Nagai
Journal:  J Clin Oncol       Date:  2006-01-01       Impact factor: 44.544

6.  Bronchial carcinoid tumours: a study on clinicopathological features and role of octreotide scintigraphy.

Authors:  M Musi; R G Carbone; C Bertocchi; D P Cantalupi; G Michetti; C Pugliese; G Virotta
Journal:  Lung Cancer       Date:  1998-11       Impact factor: 5.705

Review 7.  Update on the treatment of neuroendocrine tumors.

Authors:  Emilio Bajetta; Giuseppe Procopio; Leonardo Ferrari; Laura Catena; Michele Del Vecchio; Emilio Bombardieri
Journal:  Expert Rev Anticancer Ther       Date:  2003-10       Impact factor: 4.512

Review 8.  Treatment of carcinoid of the lung.

Authors:  Paris A Kosmidis
Journal:  Curr Opin Oncol       Date:  2004-03       Impact factor: 3.645

Review 9.  Bronchopulmonary neuroendocrine tumors.

Authors:  Bjorn I Gustafsson; Mark Kidd; Anthony Chan; Max V Malfertheiner; Irvin M Modlin
Journal:  Cancer       Date:  2008-07-01       Impact factor: 6.860

10.  Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors.

Authors:  John R Buscombe; Martyn E Caplin; Andrew J W Hilson
Journal:  J Nucl Med       Date:  2003-01       Impact factor: 10.057

View more
  1 in total

1.  Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors.

Authors:  Curtis R Chong; Lori J Wirth; Mizuki Nishino; Aileen B Chen; Lynette M Sholl; Matthew H Kulke; Ciaran J McNamee; Pasi A Jänne; Bruce E Johnson
Journal:  Lung Cancer       Date:  2014-08-27       Impact factor: 5.705

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.